论文信息 - Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation - 字舞流文

Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation

R. Gascoyne | J. Connors | R. Levy | R. Cook | G. Fradet

[1] D. Sell,et al. GOS.SP.ASS.'98: an assessment for speech disorders associated with cleft palate and/or velopharyngeal dysfunction (revised). , 1999, International journal of language & communication disorders.

[2] A. Fischer,et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. , 1998, Blood.

[3] M. Peuchmaur,et al. Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders , 1998, The Lancet.

[4] T. Pilgram,et al. The Effect of Surgeon Experience on Velopharyngeal Functional Outcome following Palatoplasty: Is There a Learning Curve? , 1998, Plastic and reconstructive surgery.

[5] J. Mulliken,et al. Velopharyngeal function in nonsyndromic cleft palate: relevance of surgical technique, age at repair, and cleft type. , 1998, The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association.

[6] E. Jaffe,et al. Complete Sustained Response of a Refractory, Post-Transplantation, Large B-Cell Lymphoma to an Anti-CD22 Immunotoxin , 1997, Annals of Internal Medicine.

[7] I. Magrath,et al. Non-Hodgkin's Lymphomas , 1990 .

[8] T. Starzl,et al. REVERSIBILITY OF LYMPHOMAS AND LYMPHOPROLIFERATIVE LESIONS DEVELOPING UNDER CYCLOSPORIN-STEROID THERAPY , 1984, The Lancet.